Nova Patents
IL190906A

Influenza virus canine/jax/05 capable of infecting canid animals and methods using it

Abstract

This record has no abstract on file.

IL190906A, drawing sheet 1
Sheet 1 of 10

Term

No projected expiry on record.

  1. Priority and filed
  2. Published
  3. Today

63 claims: 5 independent, 58 dependent

  1. 1
    An isolated polynucleotide that comprises all or part of a genomic segment or gene of an influenza virus that is capable of infecting a canid animal, wherein said influenza virus is the viral isolate designated as canine/Jax/05 (ATCC accession No. PTA-7941), wherein said influenza virus is inactivated or attenuated and wherein said influenza virus comprises a polynucleotide which encodes a polypeptide having the amino acid sequence shown in any one of SEQ ID NOs:64, 66, 68, 70, 72, 74, 76, or 78, or a functional and/or immunogenic fragment thereof, or said polynucleotide encodes a polypeptide having 99% or greater sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 64, 66, 68, 70, 72, 74, 76, or 78.
  2. 3
    An isolated influenza virus that is capable of infecting a canid animal, wherein said influenza virus is the viral isolate designated as canine/Jax/05 (ATCC accession No. PTA-7941) and wherein said influenza virus is inactivated or attenuated.
  3. 24
    The method according, to claim 22, wherein said influenza virus has an HA serotype selected from H3.
  4. 32
    A cell comprising:a) an influenza virus according to claim 3;or b) a polynucleotide that comprises all or part of a genomic segment or gene of an influenza virus of claim 3.
  5. 38
    A method for protecting a canine from an H3 influenza virus infection, wherein the method comprises administering to the canine a therapeutically effective amount of a vaccine comprising:at least one H3 influenza viral isolate, wherein said viral isolate is canine/Jax/05 (ATCC accession No. PTA-7941) and wherein said influenza virus is inactivated or attenuated, and at least one pharmaceutically acceptable excipient. /5
  6. 54
    A canine influenza vaccine, wherein the vaccine comprises:a therapeutically effective amount of at least one H3 influenza virus antigen as defined in claim 3, and at least one pharmaceutically acceptable excipient.
  7. 59
    A vaccine comprising the polynucleotide as defined in any one of claims 1, 2, 9 or 10, or comprising the influenza virus as defined in any one of claims 3-8, or comprising the polypeptide as defined in any one of claims 11-14, or comprising the composition as defined in any one of claims 15-19, or comprising the cell as defined in either of claims 32 or 33.
  8. 60
    A kit for protecting a canine from an H3 influenza virus infection, wherein the kit comprises:a therapeutically effective amount of a vaccine that comprises at least one H3 influenza virus antigen as defined in claim 3, and at least one component selected from the group consisting of: an apparatus for administering the vaccine to the canine, a pharmaceutically acceptable excipient that aids in administering the vaccine to the canine, /5 a pharmaceutically acceptable excipient that enhances the canine's immune response to the vaccine, a food to be consumed by the canine simultaneously with the vaccine, and a treat to be consumed by the canine simultaneously with the vaccine.
Independent claims8